PubMed Health⌕ Search

Biomedical subjects

M Shaklai

Publications and source records attributed to M Shaklai.

140 records · Page 8Linked to original sources
PubMed1975

Drug-induced agranulocytosis. A survey of twenty-three episodes.

Twenty-three episodes of drug-induced agranulocytosis admitted to the Beilinson Medical Center between 1960-1972 are reported. An increased incidence in patients admitted with this condition was noted over the years. Dipyrone (6 episodes in 4 patients) and chloramphenicol (5 episodes in 5 patients) were the drugs most commonly associated with this condition. Four patients died in septic shock. The increased incidence of hospital-admitted patients with drug-induced agranulocytosis is related to the increased use of drugs in the Israeli population.

Adolescent↗
PubMedDate not supplied

Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group.

To define the extent of human T-cell leukaemia virus (HTLV-I) infection among a group of Jewish immigrants to Israel with an increased frequency of adult T-cell leukaemia, various serological and molecular screening methods, including enzyme-linked immunosorbent assay (ELISA) for anti-HTLV-I, ELISA for antibody to recombinant HTLV-I p40tax protein, and molecular detection of infection by polymerase chain reaction (PCR) amplification of HTLV-I proviral DNA from peripheral blood mononuclear cell DNA, were used. By HTLV-I ELISA the overall rate of infection was 12% (24 of 208) among immigrants from Khurusan, northeastern Iran; no HTLV-I carriers were detected among 111 unselected Jewish immigrants from other parts of Iran. There was unexplained clustering of HTLV-I infection within a cohort of 32 elderly women of similar geographic origin in a home for old people--14 were seropositive by ELISA and 19 of 29 were positive by PCR. The findings in this newly identified high-risk population suggest that in addition to ELISA, other screening techniques may be required to detect all carriers in high-risk populations.

Aged↗
PubMedDate not supplied

ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.

ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone was administered on an outpatient basis to six consecutive patients with diffuse large cell lymphoma. All achieved a complete remission (CR). Two have relapsed. Actuarial analysis predicts 66.7% survival and 62.5% probability of remaining in remission at 40 months post diagnosis. The side effects of ProMACE CytoBOM were tolerable and included mainly vincristine induced peripheral neuropathy, infections and mucositis. Our results are consistent with the SWOG results, reported only recently, using the same combination chemotherapy regimen in patient with intermediate and high-grade non-Hodgkin's lymphomas. We conclude that ProMACE CytaBOM represents a highly effective and easy-to-administer regimen in patients with large cell lymphoma.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Total excision of a giant angiolipoma of chest wall with A-V malformation and with the use of an autotransfusion system.

An 18 year old girl suffering from a giant angiolipoma of back and chest wall with A-V malformation underwent total excision of the tumor in 4 stages. The first two stages included surgical ligation of the arterial blood supply to the tumor. In the third and fourth stages the tumor was resected with the use of an autotransfusion system. The last stage was complicated with massive bleeding and disseminated intravascular clotting. Control of bleeding was achieved by the use of autotransfusion system, right thoracotomy and massive transfusion of blood and its components. After long convalescence period associated with renal and respiratory failure the patient recovered completely without sequellae. This case demonstrates the complexity associated with the treatment of these rare tumors.

Adolescent↗
PubMedDate not supplied

Surgery in patients with circulating lupus anticoagulant.

Twelve surgical procedures were performed in eight patients with circulating lupus anticoagulant. Bleeding complications were noted intra and postoperatively in three patients, either with an associated hypoprothrombinemia and/or thrombocytopenia. Five patients in whom only circulating lupus anticoagulant was found had an uneventful intra and postoperative course. It is concluded that the presence of lupus anticoagulant, when unassociated with other hemostatic defects, is not a contraindication for surgery.

Adult↗